首页> Journal of clinical oncology : official journal of the American Society of Clinical Oncology> Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Vicky,Makker

第一单位： Memorial Sloan Kettering Cancer Center, New York, NY.

作者： Vicky,Makker ^[1] ; Matthew H,Taylor ^[2] ; Carol,Aghajanian ^[1] ; Ana,Oaknin ^[3] ; James,Mier ^[4] ; Allen L,Cohn ^[5] ; Margarita,Romeo ^[6] ; Raquel,Bratos ^[7] ; Marcia S,Brose ^[8] ; Christopher,DiSimone ^[9] ; Mark,Messing ^[10] ; Daniel E,Stepan ^[11] ; Corina E,Dutcus ^[12] ; Jane,Wu ^[12] ; Emmett V,Schmidt ^[13] ; Robert,Orlowski ^[13] ; Pallavi,Sachdev ^[12] ; Robert,Shumaker ^[11] ; Antonio,Casado Herraez ^[14]

作者单位： Memorial Sloan Kettering Cancer Center, New York, NY. ^[1] Oregon Health & Science University, Portland, OR. ^[2] Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. ^[3] Beth Israel Deaconess Medical Center, Boston, MA. ^[4] Rocky Mountain Cancer Center, Denver, CO. ^[5] Catalan Institute of Oncology, B-ARGO, Badalona, Spain. ^[6] MD Anderson Cancer Center España, Madrid, Spain. ^[7] Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. ^[8] Arizona Oncology Associates, Tucson, AZ. ^[9] Texas Oncology, Bedford, TX. ^[10] Formerly of Eisai Inc., Woodcliff Lake, NJ. ^[11] Eisai, Woodcliff Lake, NJ. ^[12] Merck & Co. Inc., Kenilworth, NJ. ^[13] San Carlos University Teaching Hospital, Madrid, Spain. ^[14]